daily oral glp-1 receptor agonist orforglipron for adults with obesity Pill Approved by FDA Orforglipron, an Oral Small-Molecule GLP-1
Description
Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease
We compared GLP-1RAs with SGLT2 inhibitors and metformin and found that GLP-1RAs significantly reduced the incidence of major CVEs and mortality rate compared with metformin and second- or third-line glucose-lowering medications
& Gardner, D
Dong, Y
Hormonal Modulation: Decreased free testosterone and increased SHBG following treatment reflect reduced hyperandrogenism
